Clinical Trials Logo

Clinical Trial Summary

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.


Clinical Trial Description

This is an open-label, Phase I-II, first-in-human (FIH) study for A166 as monotherapy in HER2-expressing patients who progressed on or did not respond to available standard therapies. Patients enrolled in this Phase III study must have documented HER2 positivity defined as positive on in situ hybridization (ISH) or next-generation sequencing (NGS) or HER2 expression, defined as at least 1+ by validated immunohistochemistry (IHC) test. The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have ceased to provide clinical benefit for their disease. Patients will receive study drug as a single IV infusion at the prescribed dose level in each treatment cycle. Cycles will continue until disease progression or unacceptable toxicity. The study is divided into 2 parts (Phase I and Phase II). ;


Study Design


Related Conditions & MeSH terms

  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Bile Duct Cancer
  • Bile Duct Neoplasms
  • Bladder Cancer
  • Breast Neoplasm Malignant Primary
  • Breast Neoplasms
  • Carcinoma
  • Carcinoma, Renal Cell
  • Cervical Cancer
  • Cholangiocarcinoma
  • Colo-rectal Cancer
  • Colorectal Neoplasms
  • Cystadenocarcinoma
  • Head and Neck Cancer
  • Head and Neck Carcinoma
  • Head and Neck Neoplasms
  • HER-2 Gene Amplification
  • HER2 Gene Mutation
  • HER2 Positive Gastric Cancer
  • HER2-positive Breast Cancer
  • Laryngeal Neoplasms
  • Larynx Cancer
  • Lip Cancer Stage I
  • Lip Neoplasms
  • Liver Cancer
  • Liver Neoplasms
  • Lung Cancer
  • Mouth Cancer
  • Mouth Neoplasms
  • Mucinous Adenocarcinoma Gastric
  • Mucinous Breast Cancer Recurrent
  • Mucoepidermoid Carcinoma
  • Neoplasms
  • Ovarian Neoplasms
  • Palate Cancer
  • Pancreatic Cancer
  • Pancreatic Neoplasms
  • Primary Peritoneal Carcinoma
  • Prostate Cancer
  • Prostatic Neoplasms
  • Rare Diseases
  • Rectal Cancer
  • Rectal Cancer Stage I
  • Rectal Cancer Stage II
  • Rectal Cancer Stage III
  • Rectal Neoplasms
  • Recurrent Breast Cancer
  • Recurrent Colon Cancer
  • Recurrent Gastric Cancer
  • Recurrent Ovarian Carcinoma
  • Recurrent Prostate Cancer
  • Recurrent Renal Cell Cancer
  • Salivary Gland Cancer
  • Salivary Gland Carcinoma
  • Salivary Gland Neoplasms
  • Salivary Gland Tumor
  • Skin Cancer
  • Skin Neoplasms
  • Solid Tumor
  • Stomach Neoplasms
  • Tongue Cancer
  • Tongue Neoplasms
  • Tonsil Cancer
  • Urinary Bladder Neoplasms
  • Urologic Cancer
  • Urologic Neoplasms
  • Uterine Cervical Neoplasms

NCT number NCT03602079
Study type Interventional
Source Klus Pharma Inc.
Contact Clinical Trials Info at Kluspharma
Phone 609-662-1913
Email Clinicaltrialinfo@kluspharma.com
Status Recruiting
Phase Phase 1/Phase 2
Start date July 16, 2018
Completion date May 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Recruiting NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A
Recruiting NCT03664193 - MRI-guided Stereotactic Body Radiotherapy (SBRT) With Simultaneous Integrated Boost for Prostate Cancer N/A
Not yet recruiting NCT03637543 - Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer Phase 2
Recruiting NCT03668652 - Focal Prostate Ablation Versus Radical Prostatectomy N/A
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A
Terminated NCT00953576 - Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer Phase 1/Phase 2
Recruiting NCT03568188 - Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer Phase 2
Recruiting NCT03543189 - Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy Phase 1/Phase 2
Active, not recruiting NCT00779168 - White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy Phase 1
Recruiting NCT02799706 - Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer Phase 3
Recruiting NCT01990196 - Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer Phase 2
Completed NCT02124668 - A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy Phase 2
Recruiting NCT03327675 - High Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate Cancer N/A